

January 16, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

Sub:- Board Meeting

We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, January 23, 2025, inter alia, to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December, 2024.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its 'designated persons' regarding the closure of the Trading Window from December 31, 2024 to January 25, 2025 (both days inclusive) for the purpose of approval of Unaudited Financial Results for third quarter and nine months ended December 31, 2024.

The above is for your information.

Thanking you.

Yours faithfully,
For Alivus Life Sciences Limited
(Formerly known as Glenmark Life Sciences Limited)

Rudalf Corriea
Company Secretary and Compliance officer

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@glenmarklifesciences.com | W: www.alivus.com

